You are here

F10: a novel therapeutic to treat refractory or relapsed AML

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA189480-01
Agency Tracking Number: R41CA189480
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NCI
Solicitation Number: PA13-235
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
PO Box 13714
DURHAM, NC 27709-3714
United States
DUNS: 126657514
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (919) 572-0200
Business Contact
Phone: (919) 572-0200
Research Institution
WINSTON-SALEM, NC 27109-6000
United States

 () -
 Nonprofit college or university

DESCRIPTION (provided by applicant): Acute myeloid leukemia (AML) affected ~14,600 new patients in 2013 in the US and caused over 10,000 deaths, primarily in older adults. The current chemotherapy regimen, a combination of cytarabine (AraC) and anthracyclines such as daunorubicin (DNR), has resulted in 5-year survival rates of only 30-40% (less than 10% in patients over 60 years old). The principal cause of treatment failure is chemotherapy resistance, despite an initial complete remission rate of 65%. Thelong-term goal of this STTR project is to develop a new drug for AML treatment that shows high efficacy in relapsed or refractory AML. F10 is a rationally designed molecule incorporating5-fluoro-2'-deoxyuridine-5'-O-monophosphate (FdUMP), the active metabolite of 5-fluorouracil (5-FU) chemotherapy. Studies using human and murine AML cell lines have shown that F10 has strong potency against subtypes of AML with poor clinical prognosis. The focus of these proposed studies is to establish the efficacy of

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government